Related Experiment Video
Updated: Apr 22, 2026
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Association of Inflammation-Related Biomarkers With Symptom Burden Subgroups in Patients With Gastrointestinal
Jianxin Li1, Xinyu Wu1, Yiting Yang1
1Wuxi School of Medicine, Jiangnan University (Li, Wu, Yang, and Dong, and Teng).
Background:
Patients with gastrointestinal (GI) cancers often face a high symptom burden, which may be closely linked to systemic inflammation. However, the heterogeneity of symptom burden and its association with inflammation-related biomarkers remains unclear.
Objective:
The aim of this study was to identify subgroups of symptom burden among patients with GI cancers, examine their heterogeneity, and explore potential associations with inflammation-related biomarkers.
Methods:
This cross-sectional study included 522 patients with GI cancers who completed the Memorial Symptom Assessment Scale. Inflammation-related biomarker data were calculated from blood laboratory measurements. Latent profile analysis was used to identify different subgroups of symptom burden. Binary logistic regression assessed the associations between high symptom burden and inflammation-related biomarkers. Receiver operating characteristic curve analysis evaluated their predictive performance.
Results:
Two symptom burden profiles were identified: low and high. Patients in the high symptom burden subgroup were more likely to lack medical insurance and have colon or rectal cancer. The platelet-to-lymphocyte ratio (PLR) and the prognostic nutritional index (PNI) were independently associated with high symptom burden, with areas under the curve of 0.714 and 0.734, respectively, and optimal cutoffs of 103.97 and 36.66.
Conclusion:
Patients with GI cancers exhibited 2 distinct subgroups in symptom burden. Inflammation-related biomarkers, such as PLR and PNI, demonstrated independent predictive value for identifying patients with a high symptom burden.
Implications For Practice:
Identifying PLR and PNI as predictors of high symptom burden can aid early screening and risk stratification. Their incorporation into clinical assessments may promote targeted symptom management and personalized care for patients with GI cancers.
Related Concept Videos
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis